Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
Status:
ENROLLING_BY_INVITATION
Trial end date:
2025-12-25
Target enrollment:
Participant gender:
Summary
Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and clinical ILD in patients with early lupus.
Phase:
PHASE4
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Wuhan Central Hospital Wuhan Hospital of Traditional Chinese Medicine